Societal CDMO Adds Three New Customers, Signing Agreements to Provide CDMO Services Supporting Clinical Development of Several Novel Therapeutic CandidatesGlobeNewsWire • 08/04/22
Societal CDMO to Report Financial Results for Second Quarter 2022 on August 10, 2022GlobeNewsWire • 08/03/22
Societal CDMO Selected To Provide Tech Transfer And Manufacturing Services To Support Clinical Development Of An Oral Solid Dose Product In EuropeGlobeNewsWire • 07/20/22
Societal CDMO Announces Signing of Amendment to License and Supply Agreement With Lannett for Marketing of Verapamil PM and Verelan SR ProductsGlobeNewsWire • 07/12/22
Societal CDMO Announces Key New Customer Project Within Automated Fill/Finish and Lyophilization Unit at San Diego FacilityGlobeNewsWire • 06/08/22
Societal CDMO, Inc. (SCTL) CEO David Enloe on Q1 2022 Earnings Call TranscriptSeeking Alpha • 05/12/22
Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA® in EuropeGlobeNewsWire • 05/05/22
Societal CDMO to Report Financial Results for First Quarter 2022 on May 11, 2022GlobeNewsWire • 05/04/22
Societal CDMO Secures Manufacturing and Packaging Task Order Award from National Cancer Institute (NCI)GlobeNewsWire • 04/27/22
Down 25.9% in 4 Weeks, Here's Why Societal CDMO (SCTL) Looks Ripe for a TurnaroundZacks Investment Research • 04/25/22